Selçuk Ecza Deposu Ticaret ve Sanayi A.S.(SELEC.IS)
No price history available.
Key financial summary
Financials in TRY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TRYm | 21,027 | 26,215 | 44,712 | 97,719 | 128,620 | 172,011 | N/A | N/A |
| Operating profit | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TRYm | 587 | 923 | 2,381 | 223 | 2,059 | -380 | N/A | N/A |
| EPS reported | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TRY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Selçuk Ecza Deposu Ticaret ve Sanayi A.S. operates as a crucial intermediary within the pharmaceutical supply chain, overseeing the distribution of medicinal products from manufacturers to hospitals and pharmacies. In addition to this core function, the company manages its own dedicated pharmaceutical storage facility. Established in 1958, its principal operations are based in Istanbul, Turkey. The organization is ultimately controlled as a subsidiary of Selçuk Ecza Holding A.S.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Selçuk Ecza Deposu Ticaret ve Sanayi A.S. (SELEC.IS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Selçuk Ecza Deposu Ticaret ve Sanayi A.S. operates as a crucial intermediary within the pharmaceutical supply chain, overseeing the distribution of medicinal products from manufacturers to hospitals and pharmacies. In addition to this core function, the company manages its own dedicated pharmaceutical storage facility. Established in 1958, its principal operations are based in Istanbul, Turkey. The organization is ultimately controlled as a subsidiary of Selçuk Ecza Holding A.S.